PL4034885T3 - Sposób określania siły działania terapeutycznego przeciwciała anty-clever-1 - Google Patents

Sposób określania siły działania terapeutycznego przeciwciała anty-clever-1

Info

Publication number
PL4034885T3
PL4034885T3 PL20786309.3T PL20786309T PL4034885T3 PL 4034885 T3 PL4034885 T3 PL 4034885T3 PL 20786309 T PL20786309 T PL 20786309T PL 4034885 T3 PL4034885 T3 PL 4034885T3
Authority
PL
Poland
Prior art keywords
clever
antibody
therapeutic potency
determining therapeutic
potency
Prior art date
Application number
PL20786309.3T
Other languages
English (en)
Inventor
Juho JALKANEN
Jami MANDELIN
Matti Karvonen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of PL4034885T3 publication Critical patent/PL4034885T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL20786309.3T 2019-09-24 2020-09-23 Sposób określania siły działania terapeutycznego przeciwciała anty-clever-1 PL4034885T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20195805 2019-09-24
PCT/FI2020/050620 WO2021058866A1 (en) 2019-09-24 2020-09-23 Method for determining potency of therapeutic anti-clever-1 antibody

Publications (1)

Publication Number Publication Date
PL4034885T3 true PL4034885T3 (pl) 2025-01-07

Family

ID=72752454

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20786309.3T PL4034885T3 (pl) 2019-09-24 2020-09-23 Sposób określania siły działania terapeutycznego przeciwciała anty-clever-1

Country Status (6)

Country Link
US (1) US12553906B2 (pl)
EP (1) EP4034885B1 (pl)
JP (1) JP7646640B2 (pl)
ES (1) ES3000446T3 (pl)
PL (1) PL4034885T3 (pl)
WO (1) WO2021058866A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025516877A (ja) * 2022-05-20 2025-05-30 ファロン ファーマシューティカルズ オサケ ユキチュア 抗clever-1治療の恩恵を受けるがん患者を同定する方法
LT4526683T (lt) * 2022-05-20 2026-03-10 Faron Pharmaceuticals Oy Vėžiu sergančių pacientų, tinkamų gydymui anti-clever-1, identifikavimo būdas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922554A (en) 1995-10-30 1999-07-13 The Regents Of The University Of California Inhibition of cellular uptake of cholesterol
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
DE60316106T2 (de) * 2002-01-09 2008-05-29 Faron Pharmaceuticals Oy Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
FI20090161A0 (fi) * 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
JP6907229B2 (ja) 2016-04-18 2021-07-21 ファロン ファーマシューティカルズ オサケ ユキチュア ヒト化抗clever−1抗体およびその使用

Also Published As

Publication number Publication date
JP7646640B2 (ja) 2025-03-17
JP2022549323A (ja) 2022-11-24
EP4034885B1 (en) 2024-08-21
EP4034885A1 (en) 2022-08-03
US20220357348A1 (en) 2022-11-10
US12553906B2 (en) 2026-02-17
EP4034885C0 (en) 2024-08-21
WO2021058866A1 (en) 2021-04-01
ES3000446T3 (en) 2025-02-28

Similar Documents

Publication Publication Date Title
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
IL292877A (en) Angiotensinogen (agt) irna compositions and methods of use thereof
IL280258A (en) Methods of using a gip/glp1 co-agonist for therapy
PL3638698T3 (pl) Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2
IL282424A (en) Alk2 antibodies and methods of use thereof
IL280278A (en) Fcrn antibody compositions
IL287039A (en) Cd19 antibodies and methods of using the same
DK3618928T3 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
EP4361273A4 (en) ANTI-CTLA-4 ANTIBODIES
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
IL291067A (en) Alpha-synuclein detection using beads
IL284807A (en) Antibodies specific to human nectin-2
KR102735988B9 (ko) 치료 항체 제제
IL282813A (en) Antibody formulation
EP4463485A4 (en) Tetrahedral antibodies
DK4214240T3 (da) Anti-ccr8-antistoffer
EP3841125A4 (en) MONOCLONAL ANTIBODIES TO HUMAN TIM-3
LT3681483T (lt) Terapinio baltymo farmacinės formos liofilizavimo būdas
IL281976A (en) Anti-fgfr2 antibody formulations
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
IL311043A (en) Anti-il-11rα antibodies
EP4151654A4 (en) St2 antigen binding protein
IL285546A (en) Compounds and methods for reducing kcnt1 expression
EP3825334A4 (en) HUMANIZED MONOCLONAL ANTI-HER3 ANTIBODY
IL310245A (en) Anti-hla-g antibodies